General form of registration statement for all companies including face-amount certificate companies

Income Taxes (Details Narrative) (10-K)

v3.20.2
Income Taxes (Details Narrative) (10-K) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Mar. 19, 2018
Deferred tax liability           $ 3,037,147
Intangible assets, financial reporting basis           11,038,929
Intangible assets, tax basis           $ 1,782
Net operating loss before income tax benefit $ (1,002,465) $ (881,131) $ (3,960,592) $ (4,667,848)    
Income tax benefit $ (128,129) $ (130,299) $ (602,716) (902,801) $ 258,583  
Income tax effected rate amount         $ 71,283  
Net operating loss carryforward term     P20Y      
Net operating loss carryforward, expiration date     2037      
Change in valuation of allowance     $ 668,584 329,755    
Deferred tax asset, start-up expenditures     2,909,715 1,703,904    
Deferred tax asset, loss carryforwards     4,067,602 2,665,796    
Deferred tax asset, start-up expenditures, tax effected     800,681 468,872    
Deferred tax asset, loss carryforwards, tax effected     1,119,302 $ 733,560    
Tax Cuts and Jobs Act [Member]            
Income tax description       On December 22, 2017, the Tax Cuts and Jobs Act of 2017 ("TCJA") was signed into law. Among its provisions, the TCJA reduces the statutory U.S. Corporate income tax rate from 34% to 21% effective January 1, 2018.    
Federal [Member]            
Net operating loss carryforward     1,400,000 $ 2,400,000    
Federal net operating loss carryforward     4,100,000 2,700,000    
Deferred tax loss carryforward     6,977,317 4,369,700    
Orphan Drug [Member]            
Income tax benefit     283,189      
Deferred tax loss carryforward     283,189      
General and Administrative [Member]            
Income tax benefit     1,205,811 1,356,840    
Income tax effected rate amount     $ 331,809 $ 373,368